Uldine is prescribed to help manage symptoms associated with several clinical situations. It is primarily indicated for the supportive care of conditions characterized by acute discomfort and temporary inflammation. The medication may be considered for use in situations requiring short-term symptom relief, such as temporary musculoskeletal pain or episodes of stiffness.

Uldine supports the overall management of these conditions by helping to reduce the intensity of symptoms experienced by the patient. The therapeutic approach focuses on alleviating the discomfort to **help support daily functioning.

Quick Fact: Relief for Localized Discomfort

Official Population Eligibility for Uldine

Absolute Contraindications Uldine is strictly contraindicated for any patient with a documented history of serious hypersensitivity or allergic reaction to Famotidine or to any other Histamine H₂-receptor antagonist (H₂-blocker). The intravenous formulation is not approved for use in neonates due to formulation-specific risks.

Conditional Use and Organ Function Eligibility is conditional based on patient health status as defined in regulatory documents:

• Kidney Function: Patients with moderate to severe renal impairment require a mandatory dosage adjustment, as reduced kidney function can increase the drug's concentration and the risk of central nervous system (CNS) effects.
• Comorbidities: Prior to treating gastric ulcers, the absence of gastric malignancy must be excluded as a condition for use.
• Older Adults: Geriatric patients may require closer renal function monitoring due to a heightened risk of CNS adverse reactions.

Age and Reproductive Status

• Pediatric Use: The tablet strengths are not recommended for children weighing under 40 kg. Efficacy and safety are not established for certain chronic uses in children.
• Pregnancy/Lactation: Use during pregnancy is generally not recommended unless clearly necessary. Mothers must discontinue Uldine or stop breastfeeding while using the medicine, as it is excreted in human breast milk.

Interactions with other medicines and products

The interaction profile of Uldine (Famotidine) is defined by official regulatory documentation, primarily relating to its function as an acid reducer and its clearance mechanisms. The resulting constraints on co-administration are categorized below.

Documented Exposure Changes and Restrictions

Uldine's action of raising gastric pH can significantly reduce the systemic exposure and potential efficacy of medicines that require an acidic environment for proper absorption. This includes specific oral antifungal agents (e.g., Ketoconazole, Itraconazole) and certain antivirals (e.g., Atazanavir).

Conversely, Uldine may increase the blood concentration of certain co-administered drugs, such as Tizanidine, a CYP1A2 substrate. Due to the risk of substantially increased exposure, use of this combination should be avoided, if possible, according to regulatory agencies.

Timing and Clearance Constraints

Specific medicines are required to be separated from Uldine administration to prevent reduced absorption of either agent:

• Sucralfate must not be administered within two hours of Uldine.
• Oral Ketoconazole should be administered two hours before Uldine.

Co-administration with Probenecid is advised against because it inhibits the renal tubular secretion of Uldine, which increases Uldine plasma concentrations by approximately 50%. This interaction also contributes to the heightened risk of adverse reactions in elderly patients and those with renal impairment, where reduced clearance is already a factor.

Histamine H2-Receptor Modulation

Ranitidine, marketed as Uldine, exerts its pharmacodynamic action by operating as a competitive antagonist at the Histamine H2-receptor. These receptors are expressed on the basolateral membrane of the gastric parietal cells. By binding reversibly to this site, the compound prevents the attachment and action of endogenous histamine, a primary secretagogue.

Intracellular Signaling Cascade

The occupation of the H2-receptor blocks the subsequent intracellular signaling cascade, which involves the activation of adenylate cyclase and the resultant increase in cyclic adenosine monophosphate (cAMP) concentrations. This action inhibits the downstream protein kinase activity that is necessary for the translocation and activation of the hydrogen-potassium ATPase (proton pump) molecules within the parietal cell membrane.

Gastric Acid Secretion Control

The mechanistic consequence of this molecular blockade is the inhibition of gastric acid secretion—both basal output and that stimulated by meals, histamine, or gastrin. This limits the acid load in the gastric environment. By modulating this key receptor-mediated process, the drug adjusts the overall hydrogen ion concentration within the stomach lumen.

Uldine (Famotidine) is administered via the oral route (tablets or suspension) for most uses, or by intravenous (IV) injection for short-term hospital use when oral intake is not possible.

Administration Scope

Procedural and Adjustment Rules

Frequency and Duration For acute treatment, the duration typically spans 6 to 12 weeks. Oral doses are frequently taken at bedtime for once-daily regimens, or in the morning and at bedtime for twice-daily schedules. Maintenance therapy, such as for duodenal ulcer recurrence prevention, is often dosed at 20 mg once daily and may continue for one year.

Population-Specific Adjustments Dosage adjustment is mandatory for adult patients with moderate to severe renal impairment (creatinine clearance < 60 mL/min). The dose may be reduced by 50% or the dosing interval may be extended (e.g., every 36 to 48 hours) to prevent drug accumulation. Dosing for pediatric patients is generally determined on a weight-based basis (mg/kg).

Missed Dose If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; a double dose must not be taken to compensate.

These instructions establish the precise parameters—including dose range, frequency, route, and duration—that structure the appropriate use of the medicine.

Research Evidence: Overview of Studies for Uldine

The evidence base includes randomized controlled trials (RCTs) and long-term observational studies, which have been used in research exploring how symptoms change over time over defined time intervals. Findings describe group patterns related to how symptoms evolved in the observed populations. This research contributes to the broader evidence landscape by providing insight into short-term changes.

Evidence from Clinical Trials for Ulcer Healing

Short-term, double-blind, placebo-controlled trials research examined conditions characterized by fluctuating or episodic manifestations, specifically active duodenal and gastric ulcers. These research studies monitored outcomes related to physical discomfort, which included patient-reported experiences. The primary research evaluated the endoscopic healing rate, a measure tracked to determine if the ulcer lining was restored during the study period, typically lasting up to eight weeks. However, these trials focus on the immediate healing phase, and there is limited information for long-term outcomes or recurrence rates following the initial eight weeks of treatment.

Research on Ulcer Recurrence and Managing GERD

For patients with healed duodenal ulcers, long-term maintenance trials research explored short-term symptom changes. These studies, sometimes lasting up to a year, research examined the recurrence rate of ulcers over time. Research describes patterns related to symptom variability in the observed populations over these extended durations.

In Gastroesophageal Reflux Disease (GERD), research examined its role in conditions involving periods of heightened symptoms. Trials were conducted during periods of increased symptom activity, and outcomes monitored the healing of any damage (erosive esophagitis) as well as patient-reported outcomes related to episodic or acute changes in heartburn and acid regurgitation.

Evidence Gaps and Areas of Uncertainty

The research on Uldine includes areas where the evidence quality varies across studies and where certainty remains low. For example, investigational research related to the viral illness COVID-19 explored the potential role of Uldine. The findings were mixed across the different study types (retrospective cohorts versus randomized trials). Retrospective data show patterns related to outcomes, but the results from some later, small randomized trials did not meet their primary endpoints statistically. The scientific literature indicates that the evidence quality varies across studies, and further high-quality research is needed to fully contextualize these findings.

Key Studies & References

1. H2-Receptor Antagonists for Peptic Ulcer Disease in Children: A Systematic Review and Meta-Analysis

Common questions about Uldine (FAQ)

Q: How should I store my Uldine tablets?

The official product information specifies that Uldine tablets are to be stored at a controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Brief temperature changes outside this range are usually permitted, according to the label.

The medication’s label information states that it is not intended to be stored in a freezer, consistent with storage guidelines.

Q: Does Uldine affect my concentration or ability to drive?

Official regulatory documents indicate that dizziness and drowsiness are reported side effects of Uldine. These effects are called undesirable effects, and the official label notes that they may affect an individual's performance when driving, operating machinery, or performing tasks that require concentration.

This information is provided to summarize the potential effects listed in the safety data for the product.

Storage and Disposal of Uldine

The storage requirements for Uldine (Famotidine) vary by form. Tablets and oral suspension must be stored at controlled room temperature (20 C to 25 C) and kept away from excessive heat and moisture. The intact injection solution requires refrigeration (2 C to 8 C). All forms must be stored out of the sight and reach of children and protected from light.

Specific stability rules apply: the oral suspension must be discarded 30 days after opening, and the diluted injection solution must be used within 48 hours if refrigerated. The container must remain tightly closed. Unused or expired Uldine must be disposed of in accordance with local regulations and should not be thrown into wastewater.